¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
¼¼°è ¼¼Æ÷À¯ÀüÇÐ ½ÃÀåÀº 2023³â ¾à 24¾ï 2,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 9.5%ÀÇ °ßÁ¶ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼Æ÷À¯ÀüÇÐÀº ¼¼Æ÷¿Í Á¶Á÷ »ùÇÃÀÇ ¿°»öü¸¦ ¿¬±¸ÇÏ´Â Çй®À¸·Î, À¯ÀüÁúȯ°ú ¾ÏÀ» ÀÌÇØÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¼¼Æ÷À¯ÀüÇÐÀº °³ÀÎ ¸ÂÃãÇü ÀÇ·á, Ç¥Àû ¾Ï Ä¡·á ¹× ±âŸ ºÐ¾ß¿¡ Àû¿ëµÇ¾î »ý¹°ÇÐ ¹× ÀÇÇÐ ºÐ¾ß¿¡¼ ÇʼöÀûÀÎ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù. ºñ±³À¯ÀüüºÎÇÕ¹ý, Çü±¤Á¦ÀÚ¸®ºÎÇÕ¹ý, ÇÙÇü ºÐ¼® µîÀÇ ±â¼úÀ» Ȱ¿ëÇÏ¿© À¯ÀüÀÚ ÀÌ»ó °ËÃâ ¹× ¾Ï Áø´ÜÀÌ °¡´ÉÇØÁö¸é¼ ŰƮ, ¹èÁö, ½Ã¾à, ±â±â µî ¼¼Æ÷À¯ÀüÇÐ °ü·Ã Á¦Ç°ÀÇ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
¼¼°è ¼¼Æ÷À¯ÀüÇÐ ½ÃÀåÀº ÁÖ·Î À¯Àü¼º Áúȯ°ú ¾Ï ¹ß»ý·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °í·ÉÈ Àα¸ÀÇ Áõ°¡¿Í ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, Ç¥Àû ¾Ï Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¼¼Æ÷À¯ÀüÇÐ °Ë»ç ÀåºñÀÇ ³ôÀº ºñ¿ëÀÌ ½ÃÀå È®´ë¿¡ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹Ý¸é, Çü±¤ in situ hybridization¿¡¼ ¾î·¹ÀÌ ±â¹Ý ±â¼ú·ÎÀÇ ÀüȯÀº ½ÃÀå¿¡ À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.
ÀÌ Á¶»ç¿¡¼ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«À̸ç, 2023³â ºÏ¹Ì°¡ ¼¼Æ÷À¯ÀüÇÐ ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, À̴ źźÇÑ ÀÇ·á ÀÎÇÁ¶ó¿Í ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ¿¡ ÈûÀÔÀº ¹Ù Å®´Ï´Ù. ±× ´ÙÀ½À¸·Î À¯·´ÀÌ Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº °¡Ã³ºÐ ¼Òµæ Áõ°¡, À¯Àü¼º Áúȯ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÇコÄÉ¾î ºÎ¹® È®´ë¿¡ ÈûÀÔ¾î ¿¹Ãø ±â°£ µ¿¾È ±Þ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½ÃÀå ¼¼ºÎ ºÎ¹® ¹× ÇÏÀ§ ºÎ¹®Àº ´ÙÀ½°ú °°ÀÌ ¼³¸íÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¼Æ÷À¯ÀüÇÐ ¼¼°è ½ÃÀå ÁÖ¿ä ¿ä¾à
- ¼¼Æ÷À¯ÀüÇÐ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2022-2032³â)
- Áö¿ªº° °³¿ä
- ºÎ¹®º° °³¿ä
- Á¦Ç°º°
- ±â¼úº°
- ¿ëµµº°
- ÃÖÁ¾»ç¿ëÀÚº°
- ÁÖ¿ä µ¿Çâ
- ºÒȲÀÇ ¿µÇâ
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð°ú Á¦¾È
Á¦2Àå ¼¼°èÀÇ ¼¼Æ÷À¯ÀüÇÐ ½ÃÀå Á¤ÀÇ¿Í Á¶»ç °¡Á¤
- Á¶»ç ¸ñÀû
- ½ÃÀå Á¤ÀÇ
- Á¶»ç °¡Á¤
- Æ÷ÇÔ°ú Á¦¿Ü
- Á¦ÇÑ»çÇ×
- °ø±ÞÃø ºÐ¼®
- ÀÔ¼ö °¡´É¼º
- ÀÎÇÁ¶ó
- ±ÔÁ¦ ȯ°æ
- ½ÃÀå °æÀï
- °æÁ¦¼º(¼ÒºñÀÚÀÇ °üÁ¡)
- ¼ö¿äÃø ºÐ¼®
- ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
- ±â¼úÀÇ Áøº¸
- ģȯ°æ
- ¼ÒºñÀÚ Àǽİú ¼ö¿ë
- Á¶»ç ¹æ¹ý
- Á¶»ç ´ë»ó ¿¬µµ
- ÅëÈ È¯»êÀ²
Á¦3Àå ¼¼°èÀÇ ¼¼Æ÷À¯ÀüÇÐ ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- À¯Àü¼º Áúȯ ¹× ¾Ï ¹ß»ý·ü Áõ°¡
- Ç¥Àû ¾Ï Ä¡·á¿¡ ´ëÇÑ ÁÖ¸ñ »ó½Â
- ½ÃÀå °úÁ¦
- ¼¼Æ÷À¯ÀüÇÐ ±â±âÀÇ °íºñ¿ë
- ½ÅÈï ±¹°¡ÀÇ ÀÎÁöµµ ÀúÇÏ
- ½ÃÀå ±âȸ
- ¾î·¹ÀÌ ±â¹Ý ±â¼ú·ÎÀÇ À̵¿
- ¸ÂÃãÇü ÀÇ·á ¼ºÀå
Á¦4Àå ¼¼°èÀÇ ¼¼Æ÷À¯ÀüÇÐ ½ÃÀå »ê¾÷ ºÐ¼®
- Porter's Five Forces ¸ðµ¨
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ±¸¸ÅÀÚÀÇ ±³¼··Â
- ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è
- Porter's Five Forces ¸ðµ¨·ÎÀÇ ¹Ì·¡ÁöÇâÀû Á¢±Ù¹ý
- Porter's Five ForcesÀÇ ¿µÇ⠺м®
- PESTEL ºÐ¼®
- Á¤Ä¡
- °æÁ¦
- »çȸ
- 񃬣
- ȯ°æ
- ¹ý·ü
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- ÆÄ±«Àû µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ °üÁ¡
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð°ú Á¦¾È
Á¦5Àå ¼¼Æ÷À¯ÀüÇÐ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Á¦Ç°º°, 2022-2032³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼Ò¸ðǰ
- ±â±¸
- ¼ÒÇÁÆ®¿þ¾î¿Í ¼ºñ½º
Á¦6Àå ¼¼Æ÷À¯ÀüÇÐ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ±â¼úº°, 2022-2032³â
- ºÎ¹® ´ë½Ãº¸µå
- CGH(Comparative Genomic Hybridization)
- FISH(Fluorescent In Situ Hybridization)
- ÇÙÇü ºÐ¼®
- ¸é¿ªÁ¶Á÷ÈÇÐ
- ±âŸ
Á¦7Àå ¼¼Æ÷À¯ÀüÇÐ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿ëµµº°, 2022-2032³â
- ºÎ¹® ´ë½Ãº¸µå
- À¯ÀüÁúȯ
- ¾Ï
- ¸ÂÃãÇü ÀÇ·á
- ±âŸ
Á¦8Àå ¼¼Æ÷À¯ÀüÇÐ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2022-2032³â
- ºÎ¹® ´ë½Ãº¸µå
- Àӻ󡤿¬±¸±â°ü
- Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö
- Çмú¿¬±¸±â°ü
- ±âŸ
Á¦9Àå ¼¼Æ÷À¯ÀüÇÐ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°, 2022-2032³â
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ¸ß½ÃÄÚ
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦10Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ °³¿ä
- Applied Spectral Imaging, Inc.
- °³¿ä
- À繫(µ¥ÀÌÅÍ °¡¿ë¼º¿¡ µû¶ó ´Ù¸§)
- Á¦Ç° °³¿ä
- ½ÃÀå Àü·«
- Illumina, Inc.
- Abbott Laboratories
- Irvine Scientific
- OPKO Health, Inc.
- Thermo Fisher Scientific, Inc.
- Agilent Technologies, Inc.
- PerkinElmer, Inc.
- Sysmex Corporation
- Empire Genomics, LLC
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd.
- MetaSystems
- Oxford Gene Technology
- CytoTest Inc.
Á¦11Àå Á¶»ç °úÁ¤
- Á¶»ç °úÁ¤
- µ¥ÀÌÅÍ ¸¶ÀÌ´×
- ºÐ¼®
- ½ÃÀå ÃßÁ¤
- °ËÁõ
- ÃâÆÇ
- Á¶»ç ¼Ó¼º
ksm 24.10.21
The Global Cytogenetics Market is estimated to be valued at approximately USD 2.42 billion in 2023 and is expected to grow at a robust CAGR of 9.5% over the forecast period 2024-2032. Cytogenetics, the study of chromosomes in cell and tissue samples, plays a pivotal role in understanding genetic disorders and cancers. With its applications spanning personalized medicine, targeted cancer treatment, and beyond, cytogenetics has emerged as an essential tool in the field of biology and medicine. The utilization of techniques such as comparative genomic hybridization, fluorescence in situ hybridization, and karyotyping enables the detection of genetic abnormalities and the diagnosis of cancers, driving the demand for cytogenetic products such as kits, media, reagents, and instruments.
The Global Cytogenetics Market is primarily driven by the rising incidence of genetic disorders and cancer. Increasing focus on targeted cancer therapies, along with a growing aging population and a higher prevalence of chronic diseases, further accelerates market growth. However, the high cost of cytogenetic instruments poses a challenge to market expansion. On the other hand, the transition from fluorescence in situ hybridization to array-based technologies presents lucrative growth opportunities for the market.
The key regions considered in the study include Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. In 2023, North America accounted for the largest share of the cytogenetics market, driven by a well-established healthcare infrastructure and significant investments in research and development. Europe closely follows with substantial market share. Meanwhile, the Asia-Pacific region is poised to witness the fastest growth during the forecast period, fueled by increasing disposable incomes, rising awareness about genetic disorders, and the expanding healthcare sector.
Major market players included in this report are:
- Applied Spectral Imaging, Inc.
- Illumina, Inc.
- Abbott Laboratories
- Irvine Scientific
- OPKO Health, Inc.
- Thermo Fisher Scientific, Inc.
- Agilent Technologies, Inc.
- PerkinElmer, Inc.
- Sysmex Corporation
- Empire Genomics, LLC
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd.
- MetaSystems
- Oxford Gene Technology
- CytoTest Inc.
The detailed segments and sub-segments of the market are explained below:
By Product:
- Consumables
- Instruments
- Software & Services
By Technique:
- Comparative Genomic Hybridization
- Fluorescence in Situ Hybridization
- Karyotyping
- Immunohistochemistry
- Others
By Application:
- Genetic Disorders
- Cancer
- Personalized Medicine
- Others
By End User:
- Clinical & Research Laboratories
- Pharmaceutical & Biotechnology Companies
- Academic Research Institutes
- Others
By Region:
North America:
Europe:
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia Pacific:
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America:
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of the geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of the competitive structure of the market.
- Demand-side and supply-side analysis of the market.
Table of Contents
Chapter 1. Global Cytogenetics Market Executive Summary
- 1.1. Global Cytogenetics Market Size & Forecast (2022- 2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Product
- 1.3.2. By Technique
- 1.3.3. By Application
- 1.3.4. By End User
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Cytogenetics Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory Frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Cytogenetics Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Rising Incidence of Genetic Disorders and Cancer
- 3.1.2. Increase in Focus on Targeted Cancer Treatment
- 3.2. Market Challenges
- 3.2.1. High Cost of Cytogenetic Instruments
- 3.2.2. Limited Awareness in Emerging Economies
- 3.3. Market Opportunities
- 3.3.1. Transition to Array-Based Techniques
- 3.3.2. Growth in Personalized Medicine
Chapter 4. Global Cytogenetics Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Cytogenetics Market Size & Forecasts by Product 2022-2032
- 5.1. Segment Dashboard
- 5.2. Consumables
- 5.3. Instruments
- 5.4. Software & Services
Chapter 6. Global Cytogenetics Market Size & Forecasts by Technique 2022-2032
- 6.1. Segment Dashboard
- 6.2. Comparative Genomic Hybridization
- 6.3. Fluorescence in Situ Hybridization
- 6.4. Karyotyping
- 6.5. Immunohistochemistry
- 6.6. Others
Chapter 7. Global Cytogenetics Market Size & Forecasts by Application 2022-2032
- 7.1. Segment Dashboard
- 7.2. Genetic Disorders
- 7.3. Cancer
- 7.4. Personalized Medicine
- 7.5. Others
Chapter 8. Global Cytogenetics Market Size & Forecasts by End User 2022-2032
- 8.1. Segment Dashboard
- 8.2. Clinical & Research Laboratories
- 8.3. Pharmaceutical & Biotechnology
- 8.4. Academic Research Institutes
- 8.5. Others
Chapter 9. Global Cytogenetics Market Size & Forecasts by Region 2022-2032
- 9.1. North America Cytogenetics Market
- 9.1.1. U.S. Cytogenetics Market
- 9.1.1.1. By Product breakdown size & forecasts, 2022-2032
- 9.1.1.2. By Technique breakdown size & forecasts, 2022-2032
- 9.1.1.3. By Application breakdown size & forecasts, 2022-2032
- 9.1.1.4. By End User breakdown size & forecasts, 2022-2032
- 9.1.2. Canada Cytogenetics Market
- 9.2. Europe Cytogenetics Market
- 9.2.1. U.K. Cytogenetics Market
- 9.2.2. Germany Cytogenetics Market
- 9.2.3. France Cytogenetics Market
- 9.2.4. Italy Cytogenetics Market
- 9.2.5. Spain Cytogenetics Market
- 9.2.6. Rest of Europe Cytogenetics Market
- 9.3. Asia-Pacific Cytogenetics Market
- 9.3.1. China Cytogenetics Market
- 9.3.2. India Cytogenetics Market
- 9.3.3. Japan Cytogenetics Market
- 9.3.4. Australia Cytogenetics Market
- 9.3.5. South Korea Cytogenetics Market
- 9.3.6. Rest of Asia-Pacific Cytogenetics Market
- 9.4. Latin America Cytogenetics Market
- 9.4.1. Brazil Cytogenetics Market
- 9.4.2. Mexico Cytogenetics Market
- 9.4.3 Rest of Latin America Cytogenetics Market
- 9.5. Middle East and Africa Cytogenetics Market
- 9.4.2. Saudi Arabia Cytogenetics Market
- 9.4.3. South Africa Cytogenetics Market
- 9.4.4. Rest of Middle East and Africa Cytogenetics Market
Chapter 10. Competitive Intelligence
- 10.1. Key Company SWOT Analysis
- 10.2. Top Market Strategies
- 10.3. Company Profiles
- 10.3.1. Applied Spectral Imaging, Inc.
- 10.3.1.2. Overview
- 10.3.1.3. Financial (Subject to Data Availability)
- 10.3.1.4. Product Summary
- 10.3.1.5. Market Strategies
- 10.3.2. Illumina, Inc.
- 10.3.3. Abbott Laboratories
- 10.3.4. Irvine Scientific
- 10.3.5. OPKO Health, Inc.
- 10.3.6. Thermo Fisher Scientific, Inc.
- 10.3.7. Agilent Technologies, Inc.
- 10.3.8. PerkinElmer, Inc.
- 10.3.9. Sysmex Corporation
- 10.3.10. Empire Genomics, LLC
- 10.3.11. Bio-Rad Laboratories, Inc.
- 10.3.12. F. Hoffmann-La Roche Ltd.
- 10.3.13. MetaSystems
- 10.3.14. Oxford Gene Technology
- 10.3.15. CytoTest Inc.
Chapter 11. Research Process
- 11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
- 11.2. Research Attributes